RxDoctor Payments Data

Stephen Sisselman, DO

Internal Medicine · Massapequa, NYNPI 1609948884

Payments from drug & device makers

$7,793in general payments, 2019–2025

Across 371 payments — averaging $21.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Amgen$771
  • Novo Nordisk$495
  • Novartis$427
  • Merck$310
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$7,787100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,793 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$291,917
Medicare patients
472
Services billed
4,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol43$61,028
OtezlaApremilast12$57,522
MounjaroTirzepatide38$55,641
JardianceEmpagliflozin29$41,890
OzempicSemaglutide15$18,801
EliquisApixaban11$14,183
Atorvastatin Calcium482$4,554
SynthroidLevothyroxine Sodium48$3,020
Levothyroxine Sodium168$2,642
Rosuvastatin Calcium235$2,193
Verapamil SrVerapamil Hcl11$2,007
Labetalol Hcl20$1,556
Metformin Hcl187$1,449
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,373
Losartan Potassium170$1,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,805$61,02843 claims
AmgenOtezla$771$57,52212 claims
Lilly USA, LLCMounjaro$255$55,64138 claims
Boehringer IngelheimJardiance$202$41,89029 claims
Novo NordiskOzempic$495$18,80115 claims
PfizerEliquis$287$14,18311 claims
AbbVieSynthroid$68$3,02048 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Massapequa

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →